NO20044049L - Fremstilling av N1-(2`-pyridyl)-1,2-propandiaminsulfaminsyre og den anvendelse ved syntese av biologisk aktive piperaziner - Google Patents

Fremstilling av N1-(2`-pyridyl)-1,2-propandiaminsulfaminsyre og den anvendelse ved syntese av biologisk aktive piperaziner

Info

Publication number
NO20044049L
NO20044049L NO20044049A NO20044049A NO20044049L NO 20044049 L NO20044049 L NO 20044049L NO 20044049 A NO20044049 A NO 20044049A NO 20044049 A NO20044049 A NO 20044049A NO 20044049 L NO20044049 L NO 20044049L
Authority
NO
Norway
Prior art keywords
propanediaminesulfamic
pyridyl
synthesis
preparation
acid
Prior art date
Application number
NO20044049A
Other languages
English (en)
Norwegian (no)
Inventor
Gregg Brian Feigelson
Joseph Zeldis
Anita Wai-Yin Chan
Ivo Jirkovsky
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20044049L publication Critical patent/NO20044049L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20044049A 2002-03-12 2004-09-24 Fremstilling av N1-(2`-pyridyl)-1,2-propandiaminsulfaminsyre og den anvendelse ved syntese av biologisk aktive piperaziner NO20044049L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36345702P 2002-03-12 2002-03-12
PCT/US2003/007228 WO2003078396A1 (en) 2002-03-12 2003-03-10 Preparation of n1-(2’-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines

Publications (1)

Publication Number Publication Date
NO20044049L true NO20044049L (no) 2004-09-24

Family

ID=28041771

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044049A NO20044049L (no) 2002-03-12 2004-09-24 Fremstilling av N1-(2`-pyridyl)-1,2-propandiaminsulfaminsyre og den anvendelse ved syntese av biologisk aktive piperaziner

Country Status (26)

Country Link
US (1) US6784294B2 (de)
EP (2) EP1801103B1 (de)
JP (1) JP4397693B2 (de)
KR (1) KR20040091720A (de)
CN (1) CN100341854C (de)
AR (1) AR038932A1 (de)
AT (2) ATE449073T1 (de)
AU (1) AU2003220122A1 (de)
BR (1) BR0308315A (de)
CA (1) CA2477886A1 (de)
CY (1) CY1106677T1 (de)
DE (2) DE60313301T2 (de)
DK (1) DK1483243T3 (de)
EC (1) ECSP045291A (de)
ES (2) ES2283762T3 (de)
IL (1) IL163829A0 (de)
MX (1) MXPA04008731A (de)
NO (1) NO20044049L (de)
NZ (1) NZ535170A (de)
PT (1) PT1483243E (de)
RU (1) RU2314294C2 (de)
SI (1) SI1483243T1 (de)
TW (1) TWI288642B (de)
UA (1) UA80272C2 (de)
WO (1) WO2003078396A1 (de)
ZA (1) ZA200408213B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060223824A1 (en) * 2000-11-28 2006-10-05 Wyeth Serotonergic agents
DK1408976T5 (da) 2001-07-20 2011-01-10 Psychogenics Inc Behandling af ADHD (Attention deficit hyperactivity disorder)
US7361773B2 (en) * 2002-03-12 2008-04-22 Wyeth Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
TWI288642B (en) 2002-03-12 2007-10-21 Wyeth Corp Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
JP2005527530A (ja) * 2002-03-12 2005-09-15 ワイス キラル1,4−二置換ピペラジン
US20070099931A1 (en) * 2004-03-19 2007-05-03 Wyeth Pharmaceutical dosage forms and compositions
US20050209245A1 (en) * 2004-03-19 2005-09-22 Wyeth Process for preparing N-aryl-piperazine derivatives
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
BRPI0609370A2 (pt) * 2005-03-01 2010-03-30 Wyeth Corp cloridrato de 4-ciano-n-{(2r)-2-[4-(2,3-dihidro-benzo[1,4]dioxin-5-il)-pip erazin-1-il]-propil}-n-piridin-2-il-benzamida cristalino e amorfo
CN102791691B (zh) 2010-03-12 2015-06-03 日本曹达株式会社 含有吡啶环的化合物、及卤代甲基吡啶衍生物以及四唑基肟衍生物的制造方法
EP2602248A1 (de) 2011-12-05 2013-06-12 University Of Leicester Neue Pyrrol Verbindungen
GB201310126D0 (en) * 2013-06-06 2013-07-24 Univ Leicester Novel pyrrole derivatives

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3586794T2 (de) 1984-12-21 1993-05-27 Duphar Int Res Arzneimittel mit psychotroper wirkung.
JPH01125357A (ja) 1987-11-06 1989-05-17 Dainippon Pharmaceut Co Ltd トリペプチドの誘導体
AU645681B2 (en) 1991-05-02 1994-01-20 John Wyeth & Brother Limited Piperazine derivatives
WO1994024115A1 (fr) 1993-04-16 1994-10-27 Santen Pharmaceutical Co., Ltd. Nouveau derive de piperazine
RU2118322C1 (ru) * 1993-07-05 1998-08-27 Дюфар Интернэшнл Рисерч Б.В. 2,3-дигидро-1,4-бензодиокси-5-ил-пиперазиновые производные или их соли
GB9411099D0 (en) 1994-06-03 1994-07-27 Wyeth John & Brother Ltd Piperazine derivatives
DK0763024T3 (da) * 1994-06-03 2002-12-02 Wyeth John & Brother Ltd Fremgangmåde og mellemprodukter til fremstilling af piperazinderivater
GB9514901D0 (en) * 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives
WO1997037655A1 (en) 1996-04-10 1997-10-16 Merck & Co., Inc. αvβ3 ANTAGONISTS
TWI288642B (en) 2002-03-12 2007-10-21 Wyeth Corp Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
US6713626B2 (en) * 2002-03-12 2004-03-30 Wyeth Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution

Also Published As

Publication number Publication date
JP4397693B2 (ja) 2010-01-13
JP2005526088A (ja) 2005-09-02
DE60313301T2 (de) 2007-12-27
ES2334836T3 (es) 2010-03-16
US6784294B2 (en) 2004-08-31
DE60313301D1 (de) 2007-05-31
IL163829A0 (en) 2005-12-18
BR0308315A (pt) 2004-12-28
ZA200408213B (en) 2007-03-28
MXPA04008731A (es) 2004-12-06
ES2283762T3 (es) 2007-11-01
ATE449073T1 (de) 2009-12-15
EP1801103A1 (de) 2007-06-27
CN1642916A (zh) 2005-07-20
TWI288642B (en) 2007-10-21
CN100341854C (zh) 2007-10-10
DK1483243T3 (da) 2007-08-06
RU2004130314A (ru) 2005-04-10
EP1801103B1 (de) 2009-11-18
ECSP045291A (es) 2004-10-26
WO2003078396A8 (en) 2004-01-29
DE60330199D1 (de) 2009-12-31
HK1068618A1 (en) 2005-04-29
EP1483243B1 (de) 2007-04-18
PT1483243E (pt) 2007-06-27
KR20040091720A (ko) 2004-10-28
AU2003220122A1 (en) 2003-09-29
CY1106677T1 (el) 2012-05-23
ATE360002T1 (de) 2007-05-15
TW200303751A (en) 2003-09-16
AR038932A1 (es) 2005-02-02
WO2003078396A1 (en) 2003-09-25
NZ535170A (en) 2006-03-31
SI1483243T1 (sl) 2007-08-31
EP1483243A1 (de) 2004-12-08
UA80272C2 (en) 2007-09-10
RU2314294C2 (ru) 2008-01-10
CA2477886A1 (en) 2003-09-25
US20030204087A1 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
DE60204349D1 (de) 4-(1,3,4-thiadiazolyl-2-yl)-1,4-diazabizyklo- 3.2.2 nonanderivate, ihre herstellung und ihre therapeutische verwendung
NO2015009I1 (no) Nintedanib, tautomere og salter derav, spesielt Nintedanib og fysiologiske akseptable salter derav, spesielt Nintedanib esilat; 3-Z-[l-(4-(N-((4-metylpiperazin-1-yl)-metylkarbonyl)-N-metylamino)- anilino)-1-fenylmetylen]-6-metoksykarbonyl-2-indolinon - Se blant annet kravene 1, 2, 5 (t) og 6 i basispatentet
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
ATE284886T1 (de) Benzimidazolderivate, ihre herstellung und therapeutische verwendung
DK1329456T3 (da) Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme
ATE551322T1 (de) 3-z-1-(4-(n-((4-methylpiperazin-1- yl)methylcarbonyl)-n-methylamino)anilino)1- phenylmethylen-6-methoxycarbonyl-2- indolinonmonoethansulfonat und dessen verwendung als pharmazeutische zusammensetzung
HUP0302845A3 (en) 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical
IL163552A (en) Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same
DK1267880T4 (da) Entecavir-formulering med lav dosis og anvendelse deraf
HUP0402236A3 (en) Heterocyclic compounds pharmaceutical compounds containing thereof and use thereof
DE602004022946D1 (de) 4-cyanopyrazol-3-carbonsäureamidderivate, herstellung und therapeutische anwendung davon
DE50202479D1 (de) Saure pigmentdispergatoren und pigmentzubereitungen
EE05243B1 (et) 4-(fenüülpiperasinüülmetüül)bensamiidi derivaadid, nende valmistamine ja kasutamine valu, ärevuse ja seedetrakti häirete ravis
DE60323754D1 (de) Dioxan-2-alkylkarbamaten derivaten, deren herstellung und deren therapeutischen verwendung
DE60137929D1 (de) Verwendung von lanthan bei der behandlung von knochenerkrankungen
DE60209929D1 (de) Succinate des 5,8,14-triazatetracycloä10.3.1.0 2,11 .0 4,9 ü-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
NO20044049L (no) Fremstilling av N1-(2`-pyridyl)-1,2-propandiaminsulfaminsyre og den anvendelse ved syntese av biologisk aktive piperaziner
ATE267201T1 (de) 4-(2-phenylthiazol-5-yl)1,4- diazabicyclo(3.2.2)nonanederivate, ihre herstellung und therapeutische verwendung
DE60013021D1 (de) Herstellung von S,S und R,S Aminosäuren-Isosteren
IS6378A (is) Efnasambönd og samsetningar gegn dvergveirum, notkun þeirra til lyfjagerðar og efni til að framleiða þau
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
ATE430737T1 (de) Lithium-komplexe von n-(1-hydroxymethyl-2,3- dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7, 0-tetraazacyclododecan, deren herstellung und verwendung
PL367676A1 (en) Novel heterocyclic derivatives and medicinal use thereof
NO20043295L (no) Faste salt-benzazepinforbindelser og deres anvendelse ved fremstilling av farmasoytiske forbindelser
NO20035331D0 (no) Nye heterocyklisk forbindelse og medisinsk anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application